drugset
drugset / Trial / NCT06511739

A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients

NCT06511739 ↗

Phase 2 Unknown 144 enrolled CSPC Ouyi Pharmaceutical Co., Ltd. Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A 52-Week Study of SYHX1901 tablet in Adults with non-segmental vitiligo.

Timeline

Start
2024-05-27
Primary completion
2025-08-01
Completion
2025-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject SYHX1901 Unknown — Oral

Indications

vitiligo